The United Kingdom oral mucositis market was valued at USD 95.55 Million in 2025 and is expected to grow at a CAGR of 6.60%, reaching USD 181.05 Million by 2035. The market is progressing with the growing adoption of evidence-based oral care regimens and government-backed initiatives for cancer treatment improvement. Increasing research on polymer-based coating agents and natural compounds for mucosal repair is expanding the range of therapeutic options. Expansion of hospital-based oncology units further contributes to consistent growth in the coming years.
Base Year
Historical Period
Forecast Period
In the United Kingdom, approximately 173,000 cancer deaths are projected in 2025, reflecting a significant disease burden. This rising cancer prevalence is driving the demand for oral mucositis treatments, thereby supporting market growth.
The market is driven by increasing awareness of oral health complications, rising prevalence of chronic conditions, and improved diagnostic approaches. Moreover, the growing adoption of advanced therapeutic formulations is enhancing patient comfort and recovery outcomes.
Key players in the market are driving growth through continuous product innovation, clinical research investments, strategic collaborations, and expanded distribution networks. These efforts are improving treatment accessibility and advancing the development of more effective and targeted oral mucositis management solutions.
Compound Annual Growth Rate
6.6%
Value in USD Million
2026-2035
*this image is indicative*
Oral mucositis commonly arises in patients receiving cancer therapies, leading to pain, infection risk, and delayed recovery. The market is poised to grow at a CAGR of 6.60% during the forecast period of 2026-2035, supported by an increase in cancer treatment procedures, adoption of evidence-based care protocols, and rising focus on non-invasive solutions. Government initiatives promoting cancer care quality, coupled with growing clinical awareness and hospital-based management strategies, are contributing to improved patient outcomes and expanding treatment adoption across the region.
Increasing Treatment Demand for Oral Mucositis Supporting Market Expansion
The rising treatment demand for oral mucositis is a significant driver of market growth in the United Kingdom. According to the NIHR Health Technology Assessment Report published in December 2022, oral mucositis affects around 6,000 head and neck cancer patients annually in England and Wales, highlighting the clinical importance of effective management solutions. This growing need for better therapeutic outcomes is encouraging advancements in oral care formulations, drug delivery systems, and hospital-based supportive care. As a result, ongoing innovation and improved patient management are expected to strengthen the United Kingdom oral mucositis market outlook.
Short Description: The market is experiencing notable trends, such as strategic product diversification and an increasing emphasis on supportive cancer care.
Strategic Product Expansion is Likely to Strengthen the Market Landscape in the United Kingdom
The strategic expansion of oncology supportive care portfolios through exclusive distribution partnerships is a growing trend in the market. In April 2022, Galen partnered with Sunstar Suisse S.A. to commercialize GelX® Oral Spray, designed to alleviate oral mucositis symptoms in cancer patients undergoing chemotherapy and radiation therapy. This collaboration highlights a rising focus on improving patient quality of life and accessibility to advanced supportive care solutions, a trend that is likely to enhance the market’s growth trajectory in the coming years.
Rising Focus on Supportive Cancer Care to Boost United Kingdom Oral Mucositis Market Demand
The market is witnessing a growing trend toward advanced supportive cancer care solutions that improve patient comfort and treatment adherence. In April 2024, a key development underscored this momentum when Jaguar Health entered a five-year licensing agreement with UK-based Venture Life Group for the FDA-approved oral mucositis product, Gelclair, aimed at the U.S. market. This move reflects increasing recognition of oral mucositis as a critical oncology challenge. The trend highlights the expanding adoption of clinically proven, patient-friendly therapies, driving significant market growth in the United Kingdom.
Hospitals and Clinics to Lead the Market Share by End User
There are various end users contributing to the market growth, categorized into hospitals and clinics, ambulatory surgical centers (ASCs), and others. Among these, hospitals and clinics are expected to lead the market due to their well-established infrastructure, access to advanced treatment technologies, and availability of multidisciplinary medical teams. Their capacity to manage severe cases and provide comprehensive patient care further strengthens their position as the primary choice for oral mucositis diagnosis and treatment compared with ASCs and other healthcare facilities.
The key features of the market report comprise funding and investment analysis, clinical trials and pipeline analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Amgen Inc. is one of the significant players in the market. Through its biotechnological expertise and global oncology collaborations, the company contributes to the market. Its product Kepivance (palifermin), designed to protect epithelial cells from chemotherapy-induced damage, supports advanced cancer treatment programs. Amgen’s focus on scientific innovation aligns with the region’s growing demand for supportive therapies improving cancer care outcomes.
Innovation Pharmaceuticals has emerged as a key participant in the oral mucositis market, with its flagship candidate Brilacidin-OM showing strong potential for preventing severe oral mucositis. Phase 2 results demonstrated significant efficacy and favorable tolerability, underscoring its promise to elevate the standard of care for patients undergoing intensive chemoradiation. The company is conducting further data analysis and strategic planning to guide upcoming clinical trials and strengthen collaborations with investigators and regulatory authorities across the United Kingdom.
Galera Therapeutics Inc. continues to strengthen its position in the market by advancing research in radiation-related oral mucositis management. The company’s product portfolio focuses on novel therapeutics that protect healthy tissues during cancer radiotherapy. By pursuing collaborative opportunities and aligning with clinical research standards, Galera aims to enhance patient well-being and broaden access to innovative supportive treatments that complement modern oncology practices in the region.
Soligenix Inc. has contributed to advancing clinical understanding of oral mucositis and its management among cancer patients. The company’s involvement in international trials supports the region’s emphasis on developing evidence-based supportive care. By promoting new scientific approaches that address the biological mechanisms behind mucosal damage, Soligenix is helping strengthen multidisciplinary strategies for improving patient comfort and recovery in oncology settings.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Pfizer Inc., Monopar Therapeutics Inc., Oragenics Inc., Jaguar Health Inc., EpicentRx Inc., and Enzychem Lifesciences.
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Class
Market Breakup by End User
Market Breakup by Distribution Channel
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Class |
|
| Breakup by End User |
|
| Breakup by Distribution Channel |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share